{"disease":{"id":"central-precocious-puberty-cpp","name":"central precocious puberty cpp"},"drugs":{"marketed":[{"drug_id":"histrelin-acetate","indication_name":"Central Precocious Puberty (CPP)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"HISTRELIN ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"synarel","indication_name":"Treatment of central precocious puberty (CPP) (gonadotropin-dependent precocious puberty) in children of both sexes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Synarel","generic_name":"Nafarelin Acetate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptors","drug_class":"Gonadotropin-releasing hormone agonists","quality_score":67,"revenue":null,"mechanism":"Gonadotropin-releasing hormone agonist medication"}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06720844","title":"Idiopathic Central Precocious Puberty and Associated Neurodevelopmental Syndromes and Pathologies: Evaluation of Frequency and Comparison of Diagnostic and Developmental Characteristics","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT06720623","title":"Diagnostic Power of Basal LH Compared to Peak LH After Stimulus Test in the Diagnosis of Central Precocious Puberty","phase":"","overall_status":"COMPLETED","enrollment_count":213,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT07359092","title":"Spexin and Phoenixin-20 in Girls With Central Precocious Puberty","phase":"","overall_status":"COMPLETED","enrollment_count":143,"lead_sponsor_name":"Kayseri City Hospital","has_results":false},{"nct_id":"NCT03695237","title":"A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"AbbVie","has_results":true}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}